Stayble Therapeutics AB (STU:4K4) Short Percentage of Float


What is Stayble Therapeutics AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:4K4 vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Stayble Therapeutics AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Short Percentage of Float falls into.


Stayble Therapeutics AB Business Description

Address Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.